Intranasal Morphine (MNS075) 3.75 mg
DrugIntranasal Morphine (MNS075) 3.75 mg
NCT Number: NCT00388011
Study designed to evaluate the efficacy and safety of Intranasal (IN) Morphine Nasal Spray (MNS075) 3.75 mg, 7.5 mg, 15 mg, and 30 mg, intravenous (IV) morphine 7.5 mg, or IN placebo in patients with moderate to severe post-surgical pain following orthopedic surgery. After initial dosing, up to six (6) doses of IN MNS075 7.5 mg or 15 mg for up to twenty-four (24) hours will be evaluated. The rescue dose remained the same for each.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Diagnosis and Main Criteria for Inclusion:
Healthy adult patients (18 to 76 years old), who scored PS-1 to PS-3 according to the American Society of Anesthesiologists Physical Status Classification System, requiring primary, unilateral, first metatarsal bunionectomy surgery alone or with ipsilateral hammertoe repair without additional collateral procedures.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Additional Inclusion/Exclusion Criteria May Apply
Intranasal Morphine (MNS075) 3.75 mg
Intravenous Morphine 7.5 mg
Intranasal morphine (MNS075) 7.5 mg
Intranasal morphine (MNS075) 15 mg
Intranasal morphine (MNS075) 30 mg
Intranasal placebo
Time frame: 4 hours
Time frame: Several time points
Javelin Pharmaceuticals
Industry
Randomized, Double-Blind, Placebo and Comparator-Controlled, Dose-Response Trial of the Efficacy and Safety of Intranasal Morphine, Intravenous Morphine and Placebo in Patients With Moderate to Severe Pain Following Orthopedic Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01813890
Acute Pain, Agnosia
Kaohsiung City, Taiwan
View Trial DetailsNCT07052721
Ankle Arthropathy, Clavicle Fracture
La Jolla, California, United States
View Trial DetailsNCT05101499
Akin Osteotomy, Foot Deformities
Paris, IDF, France
View Trial DetailsNCT02984462
Foot Deformities, Hallux Valgus
Bordeaux, France
View Trial Details